PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 3154438

Sensitization after transplantation.

M S Park·P I Terasaki·M Lau·Y Iwaki
View original source ↗Export metadata ↓

Abstract

1. Out of 122 sera from patients who had rejected a kidney transplant, 82% had cytotoxic antibodies to HLA. These antibodies were present in about equal frequency regardless of when the graft was rejected. Twelve patients who had rejected their grafts after 5-15 years also produced clear HLA antibodies. 2. The HLA antibodies were not directed to all the mismatches of the donor, but rather appeared to be against a few of the specificities. Thus the graft could have been rejected by a response directed at a few major determinants. Antibodies to some antigens were not detected at all. 3. Some patients produced their HLA antibodies many months after the rejection of their first graft.

Explore related subjects

Graft RejectionHLA AntigensHumansImmunizationIsoantibodiesKidney TransplantationJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M S Park, P I Terasaki, M Lau, Y Iwaki. 1987. Sensitization after transplantation.. https://pubmed.ncbi.nlm.nih.gov/3154438/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Hypoimmune platforms: from rejection to immune evasion and regulatory implications.

The growing gap between organ demand and clinical availability has renewed interest in immune-evasive graft strategies, yet rejection and lifelong immunosuppression remain major barriers to durable success. Advances in genome editing enable immune-evasive cell platforms designed to avoid immune recognition while replacing missing function in allogeneic settings. This review summarizes current strategies for engineering immune-evasive grafts that simultaneously suppress adaptive and innate immune responses. We discuss how coordinated modulation of antigen presentation and immune checkpoint pathways can protect transplanted allogeneic cells and tissues from T, NK, and macrophage-mediated rejection. We also present the emerging concept of integrating hypoimmune engineering with genetically modified porcine donors, where extensive genome editing has reduced, but not eliminated, xenogeneic immune barriers. Combining donor genome modification with immune-evasive graft design represents a promising conceptual advance toward xenograft survival, though whether full elimination of systemic immunosuppression is achievable remains to be established clinically. We further examine how the regulatory landscape for these products is evolving across major jurisdictions, and how differences in approval pathways, manufacturing standards, and long-term surveillance requirements shape the path to clinical translation. Finally, we outline the safety considerations and remaining limitations in immune evasion that must be addressed to enable clinical implementation.

Graft Rejection↗
PubMed2007

The classification and treatment of antibody-mediated renal allograft injury: where do we stand?

Since the acceptance of the detection of C4d in allografts as a reliable tool to mark a humoral alloresponse, de novo antibody-induced graft injury has attracted much attention. Antibodies and B cells are the new frontier in transplantation. At this juncture carefully designed studies are critical in order to gain solid diagnostic, therapeutic, and prognostic knowledge about the role of antibodies in graft injury and to avoid any confusion and misconception. One prerequisite is the strict adherence to refined classification systems of renal transplant rejection that carefully split and categorize different phenotypes of humoral mediated graft damage and ideally also include information on anti-donor antibody specificity and titers. Sun and colleagues follow this concept and provide evidence that mixed cellular and antibody-mediated graft rejection can respond favorably to intensified immunosuppression with tacrolimus and mycophenolate mofetil. What will the future bring to treat rejection episodes with a dominant, co-dominant, or minor antibody response?

Graft Rejection↗